Microbio Co Ltd (4128) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Microbio Co Ltd stock TWD 1.66, price TWD 13.55, that is 87.7% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 13.30 TWD – 68.73 TWD · fair‑value band 1.53 TWD – 1.83 TWD · the 13.55 TWD price screens above the 1.66 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow Microbio Co in your weekly email
Every Wednesday you see whether Microbio Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan.
Show moreShow less
The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea.
It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Stock analysis
Microbio Co Ltd (4128) currently trades at 13.55 TWD, while our model-based Fair Value estimate is 1.66 TWD, 88% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 9.98 TWD per share, and 0 of the 6 models we run sit above the 13.55 TWD price.
Bear case: the Multiples group reads lowest at 0.3800 TWD, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1.53 TWD (bear) to 1.83 TWD (bull), the price of 13.55 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Microbio Co Ltd reported revenue of 1.9B TWD in FY2025 versus 1.8B TWD in FY2021, a compound +1.5%/yr. Reported net income was −758M TWD in FY2025.
Key figures
Market cap 8.0B TWD (≈ $243M) Micro · P/E ratio 15.2 · P/S ratio 4.06 · EPS (TTM) 0.8900 TWD · Net margin 26.6% · Return on equity 2.5% · Return on assets (EBIT) −2.1% (5-year average) · Operating margin −32.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at −88%, 4128 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (0.3800 TWD to 9.98 TWD). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear1.53 TWDFair Value 1.66 TWDBull1.83 TWD
Price 13.55 TWD · Downside -87.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.7632 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Start year 2020 (pandemic). Over 10 years: +2.2% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
32.9% (2020) → −21.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+70.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +67.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 627 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−87.7% · Bottom 25%
Profitability
Return on equity (12 months)2.5% · Below median
Return on assets−6.1% · Bottom 25%
Net margin (12 months)26.6% · Top 25%
Operating margin (12 months)−32.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)5.8% · Above median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Microbio Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4128
Frequently asked questions
Is Microbio Co Ltd (4128) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 1.66 TWD versus a price of 13.55 TWD, about 88% lower (overvalued).
What is the fair value of 4128?
Our model-based fair value for Microbio Co Ltd is 1.66 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 13.55 TWD.
What is the quality score of 4128?
Microbio Co Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Microbio Co Ltd (4128)?
Our model-based price target is the fair value of 1.66 TWD (as of Nov 8, 2026) from 6 valuation models. Cautious scenario 1.53 TWD, optimistic scenario 1.83 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Microbio Co Ltd stock forecast for 2026?
Our models put fair value at 1.66 TWD, about 88% lower versus a price of 13.55 TWD (overvalued). Cautious scenario 1.53 TWD, optimistic scenario 1.83 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Microbio Co Ltd (4128)?
Microbio Co Ltd reported trailing-twelve-month revenue of about 2.0B TWD (latest available figure, as of Nov 8, 2026).
What growth is priced into Microbio Co Ltd (4128)?
For today's price to be fair in a discounted-cash-flow model, Microbio Co Ltd would have to grow free cash flow by +70.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 4128 use?
Our models discount Microbio Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.49, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Microbio Co Ltd that is +70.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Microbio Co Ltd (4128) delivered so far?
Over the past 5 years revenue at Microbio Co Ltd grew +3.4 % a year. The price currently implies free-cash-flow growth of +70.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Microbio Co Ltd (4128) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Microbio Co Ltd (+70.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Microbio Co Ltd (4128)?
The free-cash-flow yield on the price is 0.20 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Microbio Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Microbio Co Ltd (4128)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Microbio Co Ltd it is 1.66 TWD per share (as of Nov 8, 2026), against a price of 13.55 TWD. It is the blended result of 6 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Microbio Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 4128 trades above its calculated fair value: price 13.55 TWD, fair value 1.66 TWD, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4128?
No. The price is what the market pays today (13.55 TWD); the fair value is what the company's own numbers justify (1.66 TWD). For Microbio Co Ltd the two are 11.89 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Microbio Co Ltd worth?
The market values Microbio Co Ltd at about 8.0B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 13.55 TWD; our models calculate a fair value of 1.66 TWD per share.
What do the bullish and bearish scenarios say about 4128?
Our models span a range for Microbio Co Ltd: cautious scenario 1.53 TWD, base 1.66 TWD, optimistic 1.83 TWD per share (as of Nov 8, 2026, price 13.55 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4128?
Microbio Co Ltd trades at a price-to-earnings ratio of 15.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.66 TWD is built from several models across several years. Other multiples: P/B 0.9, P/S 4.1.
How solid is the balance sheet of Microbio Co Ltd (4128)?
Balance-sheet figures for Microbio Co Ltd (as of Nov 8, 2026): return on equity 2.5%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 4128 from its 52-week high?
Microbio Co Ltd trades at 13.55 TWD, about 39% below its 52-week high of 22.15 TWD and 2% above the low of 13.30 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1.66 TWD is for.
Which stocks are comparable to Microbio Co Ltd?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Microbio Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 13.55 TWD, calculated fair value 1.66 TWD (−88%), Quality Score 53/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4128 calculated?
We run Microbio Co Ltd through 6 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 1.66 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Microbio Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Microbio Co Ltd (4128)?
The closing price on Nov 9, 2026 was 13.55 TWD. Our model-based fair value is 1.66 TWD, about 88% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Microbio Co Ltd right now?
The price sits above even our optimistic bull case (1.83 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Microbio Co Ltd
How large is the market capitalisation of Microbio Co Ltd (4128)?
The market capitalisation of Microbio Co Ltd is 8.0B TWD (≈ $243M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Microbio Co Ltd (4128)?
The price-to-sales ratio of Microbio Co Ltd is 4.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Microbio Co Ltd (4128)?
Earnings per share at Microbio Co Ltd are 0.8900 TWD (price ÷ EPS = P/E 15.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Microbio Co Ltd (4128)?
The net margin of Microbio Co Ltd is 26.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Microbio Co Ltd (4128)?
The return on equity (ROE) of Microbio Co Ltd is 2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Microbio Co Ltd (4128)?
On an EBIT basis the return on assets of Microbio Co Ltd is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Microbio Co Ltd (4128)?
The operating margin of Microbio Co Ltd is −32.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Microbio Co Ltd (4128)?
Revenue at Microbio Co Ltd is growing +5.8% versus a year earlier (3y avg +3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Microbio Co Ltd (4128)?
Earnings per share at Microbio Co Ltd are growing +20.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Microbio Co Ltd (4128) hold?
Microbio Co Ltd holds more cash than debt, 14.5M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Microbio Co Ltd in the live analysis
One click puts Microbio Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026